{"id":"tll-018-tablets","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Due to limited information, the exact mechanism of TLL-018 tablets cannot be described.","oneSentence":"TLL-018 tablets' mechanism of action is not publicly available.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:39:08.270Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06887127","phase":"PHASE3","title":"A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Hangzhou Highlightll Pharmaceutical Co., Ltd","startDate":"2025-03-10","conditions":"Rheumatoid Arthritis","enrollment":350},{"nctId":"NCT06396026","phase":"PHASE3","title":"A Study of Efficacy and Safety of TLL-018 in CSU Participants","status":"RECRUITING","sponsor":"Hangzhou Highlightll Pharmaceutical Co., Ltd","startDate":"2024-12-24","conditions":"Chronic Spontaneous Urticaria","enrollment":436},{"nctId":"NCT05772520","phase":"PHASE2","title":"The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Hangzhou Highlightll Pharmaceutical Co., Ltd","startDate":"2023-01-19","conditions":"Plaque Psoriasis","enrollment":82},{"nctId":"NCT05373355","phase":"PHASE1","title":"Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria.","status":"COMPLETED","sponsor":"Hangzhou Highlightll Pharmaceutical Co., Ltd","startDate":"2022-05-10","conditions":"Chronic Spontaneous Urticaria","enrollment":41},{"nctId":"NCT05945810","phase":"PHASE1","title":"Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"Hangzhou Highlightll Pharmaceutical Co., Ltd","startDate":"2023-07-12","conditions":"Atopic Dermatitis","enrollment":28},{"nctId":"NCT06020144","phase":"PHASE3","title":"A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs","status":"UNKNOWN","sponsor":"Hangzhou Highlightll Pharmaceutical Co., Ltd","startDate":"2023-11-15","conditions":"Rheumatoid Arthritis","enrollment":450},{"nctId":"NCT05342428","phase":"PHASE1","title":"Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis","status":"COMPLETED","sponsor":"Hangzhou Highlightll Pharmaceutical Co., Ltd","startDate":"2022-06-10","conditions":"Moderate to Severe Plaque Psoriasis","enrollment":73},{"nctId":"NCT05133297","phase":"PHASE2","title":"The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hangzhou Highlightll Pharmaceutical Co., Ltd","startDate":"2022-02-16","conditions":"Rheumatoid Arthritis","enrollment":101},{"nctId":"NCT04243083","phase":"PHASE1","title":"A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of TLL018, With Food Effect, in Healthy Participants","status":"COMPLETED","sponsor":"TLL Pharmaceutical, LLC","startDate":"2020-01-26","conditions":"Healthy","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TLL-018 tablets","genericName":"TLL-018 tablets","companyName":"Hangzhou Highlightll Pharmaceutical Co., Ltd","companyId":"hangzhou-highlightll-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}